Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Comment by MassiveGainson Aug 17, 2020 1:15pm
98 Views
Post# 31418513

RE:RE:RE:RE:RE:RE:RE:next run should take to .31

RE:RE:RE:RE:RE:RE:RE:next run should take to .31

With the new Approval for Saliva test approved by the FDA, If Questcap can get into that market as well as with the already selling antibody test. There will be no stopping Questcap Capitalizing on it with the new locations for testing centres  already opened and more on the way.

Questcap 's management is hungry for success. That's the type of team you want in your corner.

If we are thinking it this way there is no way the management hasn't thought about getting in to the saliva test.

Even with its current momentum there is no stopping this from reaching the yearly high after the next financial. 

So don't sell your self short. 






 

<< Previous
Bullboard Posts
Next >>